Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317

Immunotherapy. 2020 Mar;12(4):229-234. doi: 10.2217/imt-2019-0148. Epub 2020 Mar 16.

Abstract

Metastatic colorectal cancer with BRAF mutation is a type of highly invasive malignant tumor with poor prognosis and few treatment options. Here, we report a case of a BRAF-mutant and DNA mismatch-repair deficiency colorectal cancer patient with postoperative recurrence as well as abdominal cavity and pelvic metastasis, whose condition was relieved continuously after treatment with a new anti-PD-1 antibody, BGB-A317.

Keywords: BRAF mutation; DNA mismatch repair deficiency; PD-1 inhibitors; advanced colorectal cancer; high microsatellite instability; immunotherapy.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Neoplasms / drug therapy
  • Abdominal Neoplasms / genetics
  • Abdominal Neoplasms / secondary
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / secondary
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / pathology*
  • DNA Mismatch Repair / genetics*
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immunotherapy
  • Microsatellite Instability
  • Mutation
  • Pelvic Neoplasms / drug therapy
  • Pelvic Neoplasms / genetics
  • Pelvic Neoplasms / secondary
  • Proto-Oncogene Proteins B-raf / genetics*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors
  • tislelizumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf